Key result
Nkx2.2 immunohistochemistry yields ~88% sensitivity for diagnosing Ewing sarcoma despite variable neuroendocrine expression.
Why the study?
Ewing sarcoma shares morphological overlap with other round cell tumors, especially neuroendocrine neoplasms, prompting an evaluation of Nkx2.2 immunohistochemical expression to distinguish these entities.
Does Nkx2.2 immunohistochemistry accurately distinguish Ewing sarcoma from neuroendocrine neoplasms?
Observational (n=60)
Does Nkx2.2 immunohistochemistry accurately distinguish Ewing sarcoma from neuroendocrine neoplasms?
Nkx2.2 has high sensitivity but low specificity for Ewing sarcoma, requiring caution and the use of additional markers in clinical practice.
Answers are grounded in this paper and cite their sources.
Nkx2.2 may aid differential diagnosis of Ewing sarcoma versus neuroendocrine tumors; leaves open routine adoption pending larger validation studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) conducted an observational in Ewing sarcoma and neuroendocrine neoplasms (n=60). Nkx2.2 immunohistochemistry was evaluated on Diagnostic sensitivity and specificity for Ewing sarcoma. Nkx2.2 immunohistochemistry demonstrated 88.2% sensitivity and 53.4% specificity for diagnosing Ewing sarcoma, with variable expression in neuroendocrine neoplasms.
Synapse has enriched 10 related papers. Consider them for comparative context: